Indeed, identification of inflammatory processes in early DKD with the involvement of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway (JAK/STAT) pathway [82,83] led directly to successful clinical trials with baricitinib, a potent inhibitor of this pathway, repurposed from its FDA approved role as a therapeutic for rheumatoid arthritis [84]. Here, SOAT1 is linked to diabetic kidney disease.